These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 8205592

  • 21. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lücker PW, Fuder H.
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [Abstract] [Full Text] [Related]

  • 22. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB, Lind T, Moberg S, Jansen JB, Olbe L.
    N Engl J Med; 1984 Mar 22; 310(12):758-61. PubMed ID: 6142418
    [Abstract] [Full Text] [Related]

  • 23. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL, Huang B, Amer F, Christopoulos NG.
    Clin Ther; 2004 Oct 22; 26(10):1637-43. PubMed ID: 15598480
    [Abstract] [Full Text] [Related]

  • 24. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A, Dattilo M.
    Ital J Gastroenterol Hepatol; 1997 Aug 22; 29(4):312-9. PubMed ID: 9476183
    [Abstract] [Full Text] [Related]

  • 25. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP, Campoli-Richards DM.
    Drugs; 1986 Jul 22; 32(1):15-47. PubMed ID: 3527658
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS, Berardi RR.
    J Am Pharm Assoc (Wash); 2000 Jul 22; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [Abstract] [Full Text] [Related]

  • 27. Lansoprazole: a proton pump inhibitor.
    Garnett WR.
    Ann Pharmacother; 1996 Dec 22; 30(12):1425-36. PubMed ID: 8968456
    [Abstract] [Full Text] [Related]

  • 28. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
    Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S, Italian Lansoprazole Study Group.
    Am J Gastroenterol; 2002 Jun 22; 97(6):1357-64. PubMed ID: 12094850
    [Abstract] [Full Text] [Related]

  • 29. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB, Faulds D, McTavish D.
    Drugs; 1992 Aug 22; 44(2):225-50. PubMed ID: 1382017
    [Abstract] [Full Text] [Related]

  • 30. Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors.
    Wilcox CM, Seay T, Arcury J, Hirschowitz BI.
    Scand J Gastroenterol; 2011 Mar 22; 46(3):277-80. PubMed ID: 21073392
    [Abstract] [Full Text] [Related]

  • 31. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C.
    J Gastroenterol Hepatol; 2005 Dec 22; 20(12):1886-91. PubMed ID: 16336449
    [Abstract] [Full Text] [Related]

  • 32. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome.
    Raufman JP, Collins SM, Pandol SJ, Korman LY, Collen MJ, Cornelius MJ, Feld MK, McCarthy DM, Gardner JD, Jensen RT.
    Gastroenterology; 1983 Jan 22; 84(1):108-13. PubMed ID: 6128284
    [Abstract] [Full Text] [Related]

  • 33. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD, Wilde MI.
    Drugs; 1997 Sep 22; 54(3):473-500. PubMed ID: 9279507
    [Abstract] [Full Text] [Related]

  • 34. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
    Hage E, Hendel L, Gustafsen J, Hendel J.
    Eur J Gastroenterol Hepatol; 2003 Jul 22; 15(7):781-9. PubMed ID: 12811309
    [Abstract] [Full Text] [Related]

  • 35. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
    Bown RL.
    Int J Clin Pract; 2002 Mar 22; 56(2):132-9. PubMed ID: 11926700
    [Abstract] [Full Text] [Related]

  • 36. Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
    Hirschowitz BI, Simmons J, Mohnen J.
    Aliment Pharmacol Ther; 2002 Feb 22; 16(2):303-13. PubMed ID: 11860414
    [Abstract] [Full Text] [Related]

  • 37. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
    Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT.
    Aliment Pharmacol Ther; 1993 Dec 22; 7(6):597-610. PubMed ID: 8161665
    [Abstract] [Full Text] [Related]

  • 38. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT.
    Basic Clin Pharmacol Toxicol; 2006 Jan 22; 98(1):4-19. PubMed ID: 16433886
    [Abstract] [Full Text] [Related]

  • 39. [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
    Dobrilla G, Capurso L.
    Recenti Prog Med; 2000 Apr 22; 91(4):191-210. PubMed ID: 10804753
    [Abstract] [Full Text] [Related]

  • 40. Medical treatment of Zollinger-Ellison syndrome with ranitidine.
    Vezzadini P, Bonora G, Tomassetti P, Pazzaglia M, Labò G.
    Int J Tissue React; 1983 Apr 22; 5(4):339-43. PubMed ID: 6323334
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.